Hydrocortisone butyrate clinical trials
Also written Locoid.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2006
How each study uses hydrocortisone butyrate is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 31 Mar 1982 · LOCOID · NDA 018514 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2006 (1)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2016 | 1 |
| 2017 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 2
Wake Forest University (1) · LEO Pharma (1) · Peking Union Medical College Hospital (1)
Often tested with
Tested in the same studies.
LEO 90100 (1) · Betamethasone dipropionate (1) · Betamethasone (1) · Mometasone Furoate (1)
Studies
Open first, then newest update. How each study uses hydrocortisone butyrate is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Medical and Surgical Treatment for Idiopathic Granulomatous MastitisStatus unknownPhase 4Peking Union Medical College HospitalNCT02959580Written as Hydrocortisone ButyrateHow we know
- Adherence to Topical Hydrocortisone 17-butyrate 0.1% (Locoid®) Using Different Vehicles in Adults With Atopic DermatitisCompletedPhase 4Wake Forest UniversityNCT00693693Written as hydrocortisone 17-butyrate 0.1% Cream preparationHow we know
- Vasoconstriction Trial With LEO 90100 Aerosol FoamCompletedPhase 1LEO PharmaNCT02973776Written as LocoidHow we know
Given beside what is tested · 2 — hydrocortisone butyrate is usual care or a partner of the new treatment
- Local Steroid Treatment for Idiopathic Granulomatous Mastitis (LSTIGM)Status unknownPhase 4Peking Union Medical College HospitalNCT03766997Written as Hydrocortisone Butyrate 0.1% CreamHow we know
- Efficacy and Steroid Sparing Potential Study of DGLA Cream in Early Childhood Patients With Moderate to Severe Atopic DermatitisCompletedPhase 2DS BiopharmaNCT03676933Written as Hydrocortisone Butyrate 0.1% CreamHow we know
As the comparator · 2 — what is tested is compared with hydrocortisone butyrate
- Evaluation of the Vasoconstriction Properties of MC2-01 CreamCompletedPhase 1MC2 TherapeuticsNCT03758365Written as Hydrocortisone Butyrate 0.1% CreamHow we know
- Equivalence of the Response to Vaccination of Tacrolimus Ointment to a Steroid Ointment Regimen in Children With Atopic DermatitisCompletedPhase 2Astellas Pharma IncNCT00801957Written as hydrocortisone butyrate ointment 0.1%How we know
Codes
What other systems call hydrocortisone butyrate · ClinicalTrials.gg INT002412
- MeSH (NLM) C007975hydrocortisone-17-butyrateConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 05RMF7YPWNHYDROCORTISONE BUTYRATEConfirmed FDA, NLM, Wikidata
- RxNorm 103468One source FDA
- Wikidata Q5954738hydrocortisone butyrateConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C48022Hydrocortisone ButyrateOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C007975 | hydrocortisone-17-butyrate | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 05RMF7YPWN | HYDROCORTISONE BUTYRATE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 103468 | — | One source FDA |
| Wikidata | Q5954738 | hydrocortisone butyrate | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C48022 | Hydrocortisone Butyrate | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.